MedTrace Logo

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

NCT02251951 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2015-10-08

No results posted yet for this study

Summary

The investigators propose to study the efficacy and safety of nab-Paclitaxel in a Phase II trial of patients with locally advanced or metastatic adenocarcinomas of the stomach and gastro-esophageal junction

Conditions

  • Stomach and Gastro-Esophageal Junction (GEJ) Cancer

Interventions

DRUG

nab-Paclitaxel

Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • John Souglakos, MD · University Hospital of Herklion

  • Vassilis Georgoulias, MD · University Hospital of Heraklion

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251951 on ClinicalTrials.gov